Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications.

Abstract

Reducing sugars can react non-enzymatically with amino groups of protein to form Amadori products. These early glycation products undergo further complex reactions, such as rearrangement, dehydration, and condensation, to become irreversibly cross-linked, heterogeneous fluorescent derivatives, termed advanced glycation end products (AGEs). The formation and accumulation of AGEs have been known to progress at an accelerated rate in patients with diabetes mellitus, thus being involved in the development and progression of diabetic micro- and macroangiopathy. Indeed, there is accumulating evidence that an interaction between an AGE and its receptor (RAGE) generates oxidative stress and subsequently evokes vascular inflammation and thrombosis, thereby playing a central role in diabetic vascular complications. In this paper, we review the pathophysiological role of AGE-RAGE-oxidative stress system and its therapeutic interventions in diabetic micro- and macroangiopathy.

• Authors: Sho-ichi Yamagishi
• Journal: Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy (Ther Apher Dial) Vol. 13 Issue 6 Pg. 534-9 (Dec 2009) ISSN: 1744-9987 [Electronic] Australia
• PMID: 19954478 (Publication Type: Journal Article, Review)

Chemical References

• Glycation End Products, Advanced
• Receptor for Advanced Glycation End Products
• Receptors, Immunologic

Topics

• Animals
• Diabetes Mellitus, Type 1 (complications)
• Diabetes Mellitus, Type 2 (complications)
• Diabetic Angiopathies (physiopathology, therapy)
• Glycation End Products, Advanced (metabolism)
• Humans
• Oxidative Stress
• Receptor for Advanced Glycation End Products
• Receptors, Immunologic (metabolism)